Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Back to dashboard
Company Information
About this company
Key people
John A. Donofrio
Independent Chairman of the Board
Joshua R. Disbrow
Chief Executive Officer, Director
Ryan J. Selhorn
Chief Financial Officer, Treasurer, Corporate Secretary
Jarrett T. Disbrow
Chief Business Officer
Greg Pyszczymuka
Chief Commercial Officer
Carl C. Dockery
Independent Director
Abhinav Jian
Independent Director
Vivian H. Liu
Independent Director
Click to see more
Key facts
- Shares in issue10.87m
- EPICAYTU
- ISINUS0547548588
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$22.17m
- Employees75
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.